Moderna, Inc. (MRNA) fair value analysis
S&P 500 · Updated 2026-10-19
MRNA price how computed
Valuation status
No fair-value estimate yetMRNA has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for MRNA yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $218.01
- Sector
- Healthcare
- 12-month range
- $22.36–$236.50
- Market cap
- $87B
- From 52-week high
- -7.8%
- Shares outstanding
- 399M
- Rank in Healthcare by quality score
- #197 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Moderna, Inc. is a biotechnology company that develops and manufactures messenger RNA vaccines and therapeutics for infectious diseases and oncology. The company operates globally with headquarters in the United States and conducts research, development, and manufacturing activities across multiple countries.
MRNA currently ranks #197 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $87B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $2.23B
- Net margin
- -141.4%
- EPS (TTM)
- $-7.99
- Gross margin
- 35.9%
- Debt / equity
- 0.19
- Revenue growth (3-yr avg)
- -30.7%
- Shares outstanding
- 399M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 63 · neutral
- 50-day average
- $154.93
- 200-day average
- $77.40
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-06 (pre-market)
- Last 8 quarters vs consensus
- 5 beat, 2 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▼ miss (-61.1%)
2025-12 ▲ beat (+20.1%)
2025-09 ▲ beat (+76.4%)
2025-06 ▲ beat (+29.0%)
2025-03 ▲ beat (+19.0%)
2024-12 ▼ miss (-5.4%)
2024-09 ▲ beat (+101.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 15 hold · 3 sell (23 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $124
- Target vs last price
- -43.1%
What our data shows for MRNA
- Shares are trading in the upper third of their 12-month price range of $22.36–$236.50.
- The 14-day relative strength index sits at a neutral 63.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MRNA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MRNA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for MRNA showed a shift this week as the RSI zone moved from overbought to neutral territory. The stock remains in the Healthcare sector with its valuation verdict currently awaiting full valuation assessment. This moderation in momentum suggests a potential easing of recent buying pressure.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MRNA stock undervalued?
TickrTrends has no fair-value estimate for MRNA yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is MRNA's TickrTrends verdict?
MRNA is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does MRNA compare to other Healthcare stocks?
MRNA ranks #197 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MRNA overbought or oversold?
MRNA's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does MRNA report earnings next?
MRNA's next earnings report is scheduled for 2026-11-06 (pre-market), per the published earnings calendar.
Does MRNA usually beat earnings estimates?
Over its last 8 reported quarters MRNA beat the consensus estimate 5 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MRNA?
Of 23 analysts covering MRNA, 5 rate it a buy, 15 a hold and 3 a sell - hold-leaning, with a consensus price target of $124 (-43.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.